Literature DB >> 2511965

Breast cancer and a proto-oncogene.

D M Barnes1.   

Abstract

Entities:  

Mesh：

Year:  1989        PMID： 2511965      PMCID： PMC1837980          DOI： 10.1136/bmj.299.6707.1061

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  13 in total

1.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.

Authors:  M J van de Vijver; J L Peterse; W J Mooi; P Wisman; J Lomans; O Dalesio; R Nusse
Journal:  N Engl J Med       Date:  1988-11-10       Impact factor: 91.245

2.  Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry.

Authors:  G M Clark; L G Dressler; M A Owens; G Pounds; T Oldaker; W L McGuire
Journal:  N Engl J Med       Date:  1989-03-09       Impact factor: 91.245

3.  Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis.

Authors:  J M Varley; J E Swallow; W J Brammar; J L Whittaker; R A Walker
Journal:  Oncogene       Date:  1987       Impact factor: 9.867

Review 4.  Cellular and molecular aspects of neoplastic progression in the mammary gland.

Authors:  R D Cardiff
Journal:  Eur J Cancer Clin Oncol       Date:  1988-01

5.  Amplification of c-erbB-2 and aggressive human breast tumors?

Authors:  D J Slamon; G M Clark
Journal:  Science       Date:  1988-06-24       Impact factor: 47.728

6.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

7.  Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification.

Authors:  D J Venter; N L Tuzi; S Kumar; W J Gullick
Journal:  Lancet       Date:  1987-07-11       Impact factor: 79.321

8.  Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading.

Authors:  M S Berger; G W Locher; S Saurer; W J Gullick; M D Waterfield; B Groner; N E Hynes
Journal:  Cancer Res       Date:  1988-03-01       Impact factor: 12.701

9.  Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo.

Authors:  J Yokota; T Yamamoto; K Toyoshima; M Terada; T Sugimura; H Battifora; M J Cline
Journal:  Lancet       Date:  1986-04-05       Impact factor: 79.321

10.  An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma.

Authors:  D M Barnes; G A Lammie; R R Millis; W L Gullick; D S Allen; D G Altman
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640
View more
  11 in total

1.  Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma.

Authors:  D N Poller; M Galea; D Pearson; J Bell; W J Gullick; C W Elston; R W Blamey; I O Ellis
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

2.  C-erbB-2 immunostaining: problems with interpretation.

Authors:  E W Kay; C J Walsh; M Cassidy; B Curran; M Leader
Journal:  J Clin Pathol       Date:  1994-09       Impact factor: 3.411

3.  The relationship between flow-cytometric and immunohistochemically detected c-erbB-2 expression, grade and DNA ploidy in breast cancer.

Authors:  I Brotherick; B K Shenton; W K Cowan; B Angus; C H Horne; M J Higgs; T W Lennard
Journal:  Cancer Immunol Immunother       Date:  1995-09       Impact factor: 6.968

4.  Transgenic oncogene mice. Tumor phenotype predicts genotype.

Authors:  R D Cardiff; E Sinn; W Muller; P Leder
Journal:  Am J Pathol       Date:  1991-09       Impact factor: 4.307

5.  The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases.

Authors:  N Quénel; J Wafflart; F Bonichon; I de Mascarel; M Trojani; M Durand; A Avril; J M Coindre
Journal:  Breast Cancer Res Treat       Date:  1995-09       Impact factor: 4.872

6.  Expression of epidermal growth factor receptor in breast carcinoma.

Authors:  S Lewis; A Locker; J H Todd; J A Bell; R Nicholson; C W Elston; R W Blamey; I O Ellis
Journal:  J Clin Pathol       Date:  1990-05       Impact factor: 3.411

7.  c-erbB-2 oncoprotein expression in primary and advanced breast cancer.

Authors:  C Lovekin; I O Ellis; A Locker; J F Robertson; J Bell; R Nicholson; W J Gullick; C W Elston; R W Blamey
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

8.  Immunohistochemical and other features of breast carcinomas presenting clinically compared with those detected by cancer screening.

Authors:  W K Cowan; B Angus; J Henry; I P Corbett; W A Reid; C H Horne
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

9.  Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder.

Authors:  C Wright; K Mellon; P Johnston; D P Lane; A L Harris; C H Horne; D E Neal
Journal:  Br J Cancer       Date:  1991-06       Impact factor: 7.640

10.  p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry.

Authors:  G M Horne; J J Anderson; D G Tiniakos; G G McIntosh; M D Thomas; B Angus; J A Henry; T W Lennard; C H Horne
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.